Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

NCT07575971 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Liping Dou